Is Exact Sciences Corp. Still a Buy in 2018?

There's no doubt that Exact Sciences (NASDAQ: EXAS)is a battleground stock. Bulls have long believed that the company's innovative Cologuard colon cancer detection test would convince millions of patients to be step up and get screened. Bears have pointed out that Exact has burned through massive amounts of capital in its history, and note that its test wasn't compelling enoughto convince providers and insurers to jump on board and cover it.